✦ LIBER ✦

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and pharmacodynamics of AT1001 in patients with Fabry disease and AT1001-responsive GLA mutations

✍ Scribed by Mathews Adera; Chemise Overton; Pol Boudes

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, open-label study to compar

✍ Mathews Adera; Allison Gladden; Pol Boudes 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Efficacy and safety of topical WBI-1001

✍ R. Bissonnette; C. Bolduc; C. Maari; S. Nigen; J.M. Webster; L. Tang; M. Lyle 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

Efficacy and safety of topical WBI-1001

✍ R. Bissonnette; Y. Poulin; Y. Zhou; J. Tan; H.C. Hong; J. Webster; W. Ip; L. Tan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB

A randomized, double-blind, multicenter,

✍ Hiroyoshi Ohta, Hiroshi Oka, Chie Usui, Masayuki Ohkura, Makoto Suzuki, Kusuki N 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 370 KB

A double-blind, placebo-controlled, rand

✍ Z. Hong; H. Moessler; N. Bornstein; M. Brainin; W.-D. Heiss; for the CASTA-Inves 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

A double blind, randomized, placebo cont

✍ Shahram SADREDDINI; Hamid NOSHAD; Mahshid MOLAEEFARD; Ramona MOLOUDI; Mohamad-Re 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 322 KB